Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02104583 · ClinicalTrials.gov registry record · Phase 2
Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 313
- Enrollment target
NCT02104583 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 313 participants.
The verdict
NCT02104583, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 313 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of eleclazine (GS-6615) compared to placebo on the overall occurrence of appropriate implantable cardioverter-defibrillator (ICD) interventions (antitachycardia pacing \[ATP\] or shock) in adults with ICD or cardiac resynchronization therapy-defibrillator (CRT-D).
Interventions
- DRUG Eleclazine
- DRUG Placebo to match eleclazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02104583
The ClinicalTrials.gov registry entry for NCT02104583 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eleclazine is the first listed.
NCT02104583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02104583 about?
NCT02104583 is a clinical study titled "Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator". The primary objective of this study is to evaluate the effect of eleclazine (GS-6615) compared to placebo on the overall occurrence of appropriate implantable cardioverter-defibrillator (ICD) interventions (antitachycardia pacing \[ATP\] or shock) in adults with ICD or cardiac resynchronization ther...
What is the current status of trial NCT02104583?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 313 participants. The study started on 2014-09. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02104583?
The interventions under investigation include: Eleclazine (DRUG), Placebo to match eleclazine (DRUG).
Who is sponsoring clinical trial NCT02104583?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.